Clareo Health | Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Wyeth is now a wholly owned subsidiary of Pfizer
Age
12–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male, at least 12 years old, with severe hemophilia A undergoing major elective major surgery requiring FVIII replacement for at least 6 days. Negative FVIII inhibitor test at screening and no past history of inhibitor.
Previously treated with at least 150 exposure days to any Factor VIII product
Normal hepatic and renal function tests and no other bleeding disorder
